Resverlogix Corp RVX
Trading Information
- Previous Close Price
- CA$0.09
- Day Range
- CA$0.09–0.09
- 52-Week Range
- CA$0.09–0.15
- Bid/Ask
- CA$0.09 / CA$0.10
- Shares Outstanding
- 344.29M
- Market Cap
- CA$30.99M
- Volume/Avg
- 90,500 / 29,755
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.resverlogix.com
Valuation
|
Metric
|
RVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVX
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.04 |
Interest Coverage | −1.21 |
Quick Ratio
RVX
Profitability
|
Metric
|
RVX
|
|---|---|
Return on Assets (Normalized) | −121.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<>&dV$ | LOCK|&?by& | $128B | |||
| Moderna Inc
MRNA
| LOCK|&KGjvbb | LOCK|b$x | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$D#KDFC | LOCK|%wl!$ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|K>GV@?H | LOCK|R< | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|m&>n#HV | LOCK|%X | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ls$x$M | LOCK|&H<Q# | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|cp!@c<%! | LOCK|>%M%< | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>g#J!kH | LOCK|!? | $24B | |||
| Incyte Corp
INCY
| LOCK|@lg?gM | LOCK|cg | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Y%DX<th | LOCK|XX | $15B |
United States